Achaogen Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
Sales/Revenue
18,512.00
19,970.00
26,061.00
41,773.00
11,175.00
Cost of Goods Sold (COGS) incl. D&A
506.00
-
-
-
-
Gross Income
18,006.00
-
-
-
-
SG&A Expense
29,970.00
39,398.00
52,208.00
90,680.00
136,167.00
EBIT
11,964.00
19,786.00
26,573.00
49,348.00
126,326.00
Unusual Expense
7.00
42.00
-
19,859.00
1,928.00
Non Operating Income/Expense
-
49.00
179.00
300.00
1,635.00
Interest Expense
1,341.00
397.00
699.00
2,320.00
2,855.00
Pretax Income
13,112.00
20,176.00
27,093.00
71,227.00
125,618.00
Consolidated Net Income
13,112.00
20,176.00
27,093.00
71,227.00
125,618.00
Net Income
13,112.00
20,176.00
27,093.00
71,227.00
125,618.00
Net Income After Extraordinaries
13,112.00
20,176.00
27,093.00
71,227.00
125,618.00
Net Income Available to Common
13,112.00
20,176.00
27,093.00
71,227.00
125,618.00
EPS (Basic)
0.74
1.42
1.49
3.00
3.17
Basic Shares Outstanding
17,680.60
14,210.10
18,148.00
23,707.10
39,645.60
EPS (Diluted)
0.74
1.42
1.49
3.00
3.17
Diluted Shares Outstanding
17,680.60
14,210.10
18,148.00
23,707.10
39,645.60
EBITDA
11,458.00
19,428.00
26,147.00
48,907.00
124,992.00
Non-Operating Interest Income
186.00
-
-
-
-

About Achaogen

View Profile
Address
1 Tower Place
South San Francisco California 94080
United States
Employees -
Website http://www.achaogen.com
Updated 09/14/2018
Achaogen, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E.